BioMarin halts Phase 2 Voxzogo dosing in certain patients over safety concernnews2026-03-16T18:55:04+00:00March 16th, 2026|Endpoints News|
Structure Therapeutics reports more Phase 2 data for oral GLP-1news2026-03-16T11:32:43+00:00March 16th, 2026|Endpoints News|
Roivant CEO, bullish on internal growth, dodges M&A chatternews2026-03-13T19:12:27+00:00March 13th, 2026|Endpoints News|
Immutep’s LAG-3 drug fails Phase 3 lung cancer studynews2026-03-13T15:00:10+00:00March 13th, 2026|Endpoints News|
Ultragenyx’s gene therapy hits key endpoint in Phase 3 trial for blood ammonia diseasenews2026-03-13T14:18:51+00:00March 13th, 2026|Endpoints News|
A simpler form of DNA may be key to non-viral gene therapy, study suggestsnews2026-03-12T15:31:55+00:00March 12th, 2026|Endpoints News|
FDA merges adverse event trackers into one databasenews2026-03-11T19:44:22+00:00March 11th, 2026|Endpoints News|
Study suggests long non-coding RNA has potential as new class of genetic medicinenews2026-03-10T20:02:18+00:00March 10th, 2026|Endpoints News|
Vertex reports Phase 3 win for kidney drug, will seek FDA approvalnews2026-03-10T15:20:08+00:00March 10th, 2026|Endpoints News|
China is going after the world’s most expensive drugs: Endpoints Signalnews2026-03-10T13:00:49+00:00March 10th, 2026|Endpoints News|
